Arcutis Biotherapeutics (ARQT) EPS (Diluted) Growth (1y) (2020 - 2026)
Analysis
Arcutis Biotherapeutics (ARQT) EPS (Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -11.18% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn | 188.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 188.29% |
| Mar 31, 2026 | 56.09% |
| Dec 31, 2025 | 253.03% |
| Sep 30, 2025 | 116.69% |
| Jun 30, 2025 | 70.48% |
| Mar 31, 2025 | 37.60% |
| Dec 31, 2024 | 90.67% |
| Sep 30, 2024 | 53.92% |
| Jun 30, 2024 | 63.33% |
| Mar 31, 2024 | 75.67% |
| Dec 31, 2023 | 26.92% |
| Sep 30, 2023 | 61.56% |
| Jun 30, 2023 | 12.69% |
| Mar 31, 2023 | -1.40% |
| Dec 31, 2022 | 9.60% |
| Sep 30, 2022 | -65.64% |
| Jun 30, 2022 | -56.97% |
| Mar 31, 2022 | -69.41% |
| Dec 31, 2021 | -51.56% |
| Sep 30, 2021 | -12.26% |